吉西他滨联合顺铂对晚期肺鳞癌及肺腺癌治疗的临床疗效比较

Conparison of Clinical Efficacy Analysis of Gemcitabine Combined with Cisplatin in Treatment of Advanced Lung Squamous Cell Carcinoma and Lung Adenocarcinoma

目的探讨晚期肺鳞癌与肺腺癌采用吉西他滨联合顺铂的治疗效果。方法于2014年4月至2016年3月期间,随机抽取本院经病理确诊的晚期肺鳞癌与肺腺癌患者78例,根据疾病类型分为两组,39例肺鳞癌患者作为甲组,39例肺腺癌患者作为乙组。甲组与乙组患者都实施吉西他滨联合顺铂化疗,化疗时间为3周,每个患者进行4个周期的治疗。结果甲组患者治疗总有效率74.36%,与乙组患者的76.92%相比较,无统计学意义(P>0.05);甲组患者12个月生存率66.67%,比乙组患者的28.21%高(P<0.05);甲组患者24个月生存率15.38%,与乙组患者的12.82%相比较,无统计学意义(P>0.05);甲组患者生存期7~25个月,平均生存期14个月,乙组患者生存期4~30个月,平均生存期10个月,甲组患者生存期高于乙组;甲组患者不良反应发生率48.71%,与乙组患者的35.90%相比较,无统计学意义(P>0.05)。结论晚期肺鳞癌与肺腺癌采用吉西他滨联合顺铂的治疗效果类似,但与肺腺癌相比,肺鳞癌的12个月生存率与生存期更好。

Objective To explore the therapeutic effect of gemcitabine combined with cisplatin on advanced lung squamous cell carcinoma and lung adenocarcinoma.Methods From April 2014 to March 2016,78 patients with advanced lung squamous cell carcinoma and lung adenocarcinoma confi rmed pathologically in our hospital were randomly selected and divided into 2 groups according to disease types,39 patients with lung squamous cell carcinoma as group A and 39 patients with lung adenocarcinoma as group B.Both group A and group B patients received gemcitabine plus cisplatin chemotherapy for 3 week,and each patient received 4 period treatments.Results The total eff ective rate of group A was 74.36%,which was not statistically signifi cant compared with 76.92%of group B(P>0.05).The 12-month survival rate of patients in group A was 66.67%,higher than 28.21%in group B(P<0.05).The 24-month survival rate of patients in group A was 15.38%,which was not statistically signifi cant compared with 12.82%of patients in group B(P>0.05).The survival time of patients in group A was 7-25 months,with an average survival time of 14 months.The survival time of patients in group B is 4-30 months,with an average survival time of 10 months.The average survival time of patients in group A is higher than that in group B.The incidence of adverse reactions in group A was 48.71%,which was not statistically signifi cant compared with 35.89%in group B(P>0.05).Conclusion The treatment eff ect of gemcitabine combined with cisplatin for advanced lung squamous cell carcinoma and lung adenocarcinoma is similar,but compared with lung adenocarcinoma,the 12-month survival rate and survival time of lung squamous cell carcinoma are better.